Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
about
Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine ModelThe Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaIn vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cellsEffects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.The drug-target residence time model: a 10-year retrospective.Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.A [(32)P]NAD(+)-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitorsProtein conformational flexibility modulates kinetics and thermodynamics of drug binding.X-Linked Inhibitor of Apoptosis Protein (XIAP) is a Client of Heat Shock Protein 70 (Hsp70) and a Biomarker of its Inhibition.Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.Hsp90 and angiogenesis in bone disorders--lessons from the avian growth plate.
P2860
Q27312452-1A6FE8E5-49A9-4455-80BF-2E1F64FACDB5Q27851619-F197497C-219E-4CDA-88D0-9D58B9782DEAQ35528633-0518C047-040E-4AB0-9EA6-06973AED1CBCQ35691439-257BD477-5E2A-4633-9EB6-65FFC75C2ED4Q36274172-775C1A1F-ED19-4A36-A270-74C65BBECA91Q37204596-C7FDDE66-2B6D-4760-BD00-3F49865282F7Q38672210-B0650E9D-0B9F-40E5-8916-80D6580CD466Q39491265-AF31CC6E-5A06-4048-A146-9104284A4080Q42732595-ED177D38-A431-4ADA-B24D-456A2FFA87AFQ47259436-830CDF76-2DDA-45BB-9882-E467ACC6B1B3Q47279123-440064E1-8C99-4856-87ED-5A72270C23EBQ48210380-D3E15B9D-854D-4706-9C88-5D09258B9E77Q54216878-93F6A5DE-FAFA-4B0D-BD2A-464372102050Q54590776-11FCD0CA-42A9-43DC-A06B-53D254321914
P2860
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@ast
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@en
Hsp90
@nl
type
label
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@ast
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@en
Hsp90
@nl
prefLabel
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@ast
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@en
Hsp90
@nl
P2093
P2860
P356
P1476
Hsp90 (heat shock protein 90) ...... nd tumor growth arrest in vivo
@en
P2093
Bonnie Tillotson
Brian Thomas
Christian C Fritz
Emmanuel Normant
Janid A Ali
John MacDougall
Julian Adams
Kelly Slocum
P2860
P304
39835-39843
P356
10.1074/JBC.M110.141580
P407
P577
2010-10-12T00:00:00Z